TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8084436

Group type: EXPERIMENTAL
Intervention: Calcitonin and arginine-lysine-glycerophosphoric acid-lactose association
Number of subjects: 2

Group type: COMPARATOR
Intervention: Calcitonin
Number of subjects: 2
Study: 2510877

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg, increased to 25 mg if needed)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Sustained release verapamil (120 mg, increased to 240 mg if needed)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and verapamil (25 mg and 240 mg)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Regimen V (combination treatment)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 369

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Combining verapamil with hydrochlorothiazide
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Combining hydrochlorothiazide with verapamil
Number of subjects: 369
Study: 4417365

Group type: EXPERIMENTAL
Intervention: Anonymous group administered questionnaires
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Anonymous interviews
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Interviews with subject's name verified at the outset
Number of subjects: 66

Group type: COMPARATOR
Intervention: All assessment conditions
Number of subjects: 66
Study: 31623758

Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Number of subjects: 3576

Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin monotherapy
Number of subjects: 3576
Study: 26773736

Group type: EXPERIMENTAL
Intervention: Curved abutment design (experimental)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Divergent abutment design (control)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both abutment designs (Curved and Divergent)
Number of subjects: 26
Study: 24357450

Group type: EXPERIMENTAL
Intervention: Subfascial endoscopic perforating vein surgery (SEPS) with ambulatory compression therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Incomplete SEPS procedure
Number of subjects: 94

Group type: COMPARATOR
Intervention: New incompetent perforating veins
Number of subjects: 94

Group type: COMPARATOR
Intervention: Deep vein incompetence and treatment of superficial venous incompetence
Number of subjects: 94
Study: 24922652

Group type: EXPERIMENTAL
Intervention: HyperBaric Oxygen (HBO) session the day before intervention (group A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Air breathing for 40 min in a hyperbaric chamber (placebo group, group B)
Number of subjects: 21
Study: 22317061

Group type: EXPERIMENTAL
Intervention: Stay@Work Participatory Ergonomics programme (PE)
Number of subjects: 3047

Group type: COMPARATOR
Intervention: Control group (no PE)
Number of subjects: 3047
Study: 19048230

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17296414

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 15896236

Group type: EXPERIMENTAL
Intervention: 200 mg of itraconazole alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: 200 mg of itraconazole co-administered with antacid suspension
Number of subjects: 12
Study: 11971884

Group type: EXPERIMENTAL
Intervention: Intervention aimed at clinicians to improve patient health
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual-randomized trials
Number of subjects: 0
Study: 9708455

Group type: EXPERIMENTAL
Intervention: abciximab (ReoPro, c7E3 Fab) bolus plus 12-hour infusion
Number of subjects: 2099

Group type: COMPARATOR
Intervention: abciximab (ReoPro, c7E3 Fab) bolus only
Number of subjects: 2099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: abciximab (ReoPro, c7E3 Fab)
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: bolus-plus-infusion treatment
Number of subjects: 2099
Study: 7634747

Group type: EXPERIMENTAL
Intervention: Ischaemic exercise
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Arterial occlusion
Number of subjects: 26
Study: 2694463

Group type: EXPERIMENTAL
Intervention: Mefloquine plus sulfadoxine‐pyrimethamine (MSP)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 193
Study: 354732

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment (pimozide)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment (fluphenazine)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Drug-free schizophrenic patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Patients who remitted after neuroleptic withdrawal
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Catatonic schizophrenic patients
Number of subjects: 31
Study: 31699604

Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention for refugees (FSI-R)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 40
Study: 30045592

Group type: EXPERIMENTAL
Intervention: Thermal RF; thermal RF neurolysis was applied with a time of 60 seconds at 80º C, repeated twice after needle-tip rotation.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pulsed RF; super voltage pulsed RF was applied with a time of 360 seconds at 42º C, with a pulse width of 20 m/sec and voltage of 60‐70 v.
Number of subjects: 80
Study: 26323328

Group type: EXPERIMENTAL
Intervention: Vitamin D intervention (details not specified)
Number of subjects: 338
Study: 25573317

Group type: EXPERIMENTAL
Intervention: 2% H2 inhalation for 1 h at 1 h and 6 h after CLP operation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sepsis group (control)
Number of subjects: 84
Study: 22537766

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 20
Study: 20191522

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 0
Study: 18823458

Group type: EXPERIMENTAL
Intervention: Ringer's lactate (RL) solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: Gelatin-containing solution
Number of subjects: 44
Study: 16077392

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 100 mg/kg
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 12623505

Group type: EXPERIMENTAL
Intervention: Cisplatin-methotrexate chemotherapy (3 courses)
Number of subjects: 317

Group type: COMPARATOR
Intervention: No pretreatment (control group)
Number of subjects: 317
Study: 10349036

Group type: EXPERIMENTAL
Intervention: D,L-fenfluramine (FEN) 60 mg oral dose
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8951631

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer toothpaste
Number of subjects: 129

Group type: COMPARATOR
Intervention: Conventional fluoride toothpastes (including a children's fluoride toothpaste)
Number of subjects: 129
Study: 1958601

Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% bupivacaine with 5 micrograms/ml epinephrine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 20 ml 0.5% bupivacaine without epinephrine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups (bupivacaine with and without epinephrine)
Number of subjects: 10
Study: 7128675

Group type: EXPERIMENTAL
Intervention: PB-sodium 130 mg i.v. (IV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PB sodium 10 mg i.m. (IM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PB acid 100 mg orally (PO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Epileptic patients (treated with phenytoin or carbamazepine)
Number of subjects: 12
Study: 31154591

Group type: EXPERIMENTAL
Intervention: Evaluation of patients' religious beliefs in RCTs related to bone grafting procedures
Number of subjects: 0
Study: 30721294

Group type: EXPERIMENTAL
Intervention: MRI-guided treat-to-target strategy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional treat-to-target strategy
Number of subjects: 200
Study: 28196467

Group type: EXPERIMENTAL
Intervention: Invitation letter to participate in screening (IG1)
Number of subjects: 15965

Group type: EXPERIMENTAL
Intervention: Invitation letter and informative leaflet (IG2)
Number of subjects: 15965

Group type: EXPERIMENTAL
Intervention: Invitation letter, informative leaflet, and phone call reminder (IG3)
Number of subjects: 15965

Group type: COMPARATOR
Intervention: No intervention group (NIG)
Number of subjects: 15965
Study: 24575793

Group type: EXPERIMENTAL
Intervention: Sequential erlotinib (150 mg/day on day 15 through day 28) and gemcitabine (1250 mg/m2 Day 1, 8 q28 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (1000 mg/m2 Days 1, 8, 15 q28 days)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sequential erlotinib and gemcitabine (EG-arm)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (G-arm)
Number of subjects: 54
Study: 25070687

Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 300

Group type: COMPARATOR
Intervention: cyclosporine
Number of subjects: 300
Study: 22357185

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Insulin glargine (IG)
Number of subjects: 390
Study: 19095219

Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 250
Study: 17898508

Group type: EXPERIMENTAL
Intervention: Apple polyphenols (600 mg/day for 12 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Hop bract polyphenol-containing capsules (600 mg/day for 12 weeks)
Number of subjects: 71
Study: 14986055

Group type: EXPERIMENTAL
Intervention: Supine/left decubitus scanning
Number of subjects: 50

Group type: COMPARATOR
Intervention: Supine/prone scanning
Number of subjects: 50
Study: 11602484

Group type: EXPERIMENTAL
Intervention: Behçet's syndrome with arthritis
Number of subjects: 44

Group type: COMPARATOR
Intervention: Behçet's syndrome without arthritis
Number of subjects: 44

Group type: COMPARATOR
Intervention: Active rheumatoid arthritis
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 44
Study: 9602763

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg, 3 times per day for 8 days
Number of subjects: 209

Group type: COMPARATOR
Intervention: Indomethacin 50 mg, 3 times per day for 4 days
Number of subjects: 209
Study: 8137332

Group type: EXPERIMENTAL
Intervention: Retinoid isotretinoin
Number of subjects: 0
Study: 3344690

Group type: EXPERIMENTAL
Intervention: Continuing instruction and support through 10 staff-initiated telephone contacts of 5 minutes each every 2 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Daily self-monitoring and adherence instructions
Number of subjects: 103

Group type: COMPARATOR
Intervention: Weekly self-monitoring only
Number of subjects: 103
Study: 31899001

Group type: EXPERIMENTAL
Intervention: HDA-R (high-disease-activity relapsing)
Number of subjects: 6647

Group type: EXPERIMENTAL
Intervention: HDA-L (high-disease-activity lesion)
Number of subjects: 6647

Group type: COMPARATOR
Intervention: LDA (low-disease-activity)
Number of subjects: 6647
Study: 31563387

Group type: EXPERIMENTAL
Intervention: Ankle eversion taping
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 15

Group type: COMPARATOR
Intervention: No taping
Number of subjects: 15
Study: 28425778

Group type: EXPERIMENTAL
Intervention: Meditation Awareness Training (MAT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 73
Study: 26162281

Group type: EXPERIMENTAL
Intervention: Life Adaptation Skills Training (LAST) program, 24 sessions, plus 24 phone contacts for support
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (phone contact only, 24 times)
Number of subjects: 68
Study: 24266074

Group type: EXPERIMENTAL
Intervention: Sacral canal injection
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lumbar oblique wrench
Number of subjects: 65
Study: 16817651

Group type: EXPERIMENTAL
Intervention: Intense anxiety response during flying
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Moderate excitement response during flying
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Exercise and excitement
Number of subjects: 28
Study: 14521170

Group type: EXPERIMENTAL
Intervention: Insulin regimen with pre‐breakfast injections
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin regimen with pre‐dinner injections
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin regimen with bedtime injections
Number of subjects: 16

Group type: COMPARATOR
Intervention: Overall quality of glycemic control (HbAIC) for different regimens
Number of subjects: 16
Study: 10561203

Group type: EXPERIMENTAL
Intervention: Formestane (250 mg intramuscularly biweekly)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Megestrol acetate (160 mg orally daily)
Number of subjects: 128
Study: 8554206

Group type: EXPERIMENTAL
Intervention: Intensive therapy with sulfonylurea
Number of subjects: 4209

Group type: EXPERIMENTAL
Intervention: Intensive therapy with insulin
Number of subjects: 4209

Group type: COMPARATOR
Intervention: Conventional therapy (diet alone)
Number of subjects: 4209

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 4209
Study: 1649683

Group type: EXPERIMENTAL
Intervention: Cisplatin plus Vindesine (CDDP + VDS)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) alone
Number of subjects: 160
Study: 6347243

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 30736083

Group type: EXPERIMENTAL
Intervention: Malagueta (30 CH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28421205

Group type: EXPERIMENTAL
Intervention: 470 nm light
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 635 nm light
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Blue light stimulation
Number of subjects: 103
Study: 25724655

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 0
Study: 23903090

Group type: EXPERIMENTAL
Intervention: Active microcurrent with silver-coated nylon dressing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham microcurrent with silver-coated nylon dressing
Number of subjects: 30
Study: 21706526

Group type: EXPERIMENTAL
Intervention: BSF+ (ongoing MI training with audio-recorded feedback in peer groups)
Number of subjects: 45

Group type: COMPARATOR
Intervention: BSF (workshop-only MI training)
Number of subjects: 45

Group type: COMPARATOR
Intervention: UPI (usual prison planning interviews)
Number of subjects: 45
Study: 19466447

Group type: EXPERIMENTAL
Intervention: Lowlanders tested at sea level (LL-SL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Native highlanders tested at altitude (HAN)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lowlanders tested at altitude (LL-HA)
Number of subjects: 90
Study: 16715913

Group type: EXPERIMENTAL
Intervention: Methylergometrine 0.2 mg bolus (MEM group; n = 34)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Oxytocin 10 IU over 30 seconds (OX 30 s group; n = 34)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Oxytocin 10 IU over 5 minutes (OX 5 m group; n = 34)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Oxytocin 10 IU over 15 minutes (OX 15 m group; n = 34)
Number of subjects: 136
Study: 15477411

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d during the open-label period
Number of subjects: 15432

Group type: COMPARATOR
Intervention: Drug-washout period (no statin therapy)
Number of subjects: 15432
Study: 11156874

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments (Hirudin and Unfractionated heparin)
Number of subjects: 0
Study: 9158354

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 ng/ml)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 ng/ml)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 49
Study: 7967730

Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside (3 g/m2 every 12 h for 6 days) with etoposide (100 mg/m2 days 7-9)
Number of subjects: 131

Group type: COMPARATOR
Intervention: High-dose cytosine arabinoside (3 g/m2 every 12 h for 6 days) alone
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Combination regimen (high-dose cytosine arabinoside with etoposide)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 5-year disease-free survival
Number of subjects: 131
Study: 3310634

Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g per day
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cimetidine 400 mg per day
Number of subjects: 71
Study: 29534975

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS) to the left DLPFC
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS) to the left DLPFC
Number of subjects: 32
Study: 28245852

Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 0
Study: 25636672

Group type: EXPERIMENTAL
Intervention: Preoperative embolization
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Preoperative embolization (hypervascular metastases)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (hypervascular metastases)
Number of subjects: 45
Study: 23656351

Group type: EXPERIMENTAL
Intervention: High-dose L-arginine (6 g/day for at least 24 months)
Number of subjects: 4
Study: 21095149

Group type: EXPERIMENTAL
Intervention: PTH(1-84) therapy
Number of subjects: 119
Study: 18978618

Group type: EXPERIMENTAL
Intervention: 4 weeks of training on foot speed (FS) and choice reaction (REACT) drills
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 23
Study: 16973640

Group type: EXPERIMENTAL
Intervention: Digital anesthesia (1% lidocaine)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Local anesthesia (1% lidocaine)
Number of subjects: 55
Study: 14693302

Group type: EXPERIMENTAL
Intervention: SU + RSG
Number of subjects: 824

Group type: COMPARATOR
Intervention: SU + placebo
Number of subjects: 824
Study: 11027909

Group type: EXPERIMENTAL
Intervention: Active (deep) PC6 acupuncture
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (superficial) acupuncture
Number of subjects: 33
Study: 8932759

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 mu g inserted vaginally 12 hours before induced abortion (Group B)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mu g inserted vaginally 12 hours before induced abortion (Group A)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 mu g orally 12 hours before induced abortion (Group C)
Number of subjects: 129
Study: 1448663

Group type: EXPERIMENTAL
Intervention: CCNU 130 mg/m2, q.6 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: VM‐26 100 mg/m2 on day 1, plus CCNU 130 mg/m2 on day 2, q.6 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: HeCNU
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Mizonidazole 12 mg/m2 total dose in 9 fractions
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2 on days 1,8, 15 and 21 of radiation therapy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Procarbazine, AZQ or DDMP used as single agents
Number of subjects: 5
Study: 3881501

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (400 micrograms daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30523750

Group type: COMPARATOR
Intervention: Letrozole (2.5 mg/d) for 14 weeks (Group A)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/d) plus letrozole for 14 weeks (Groups B, C, D)
Number of subjects: 307
Study: 29768340

Group type: EXPERIMENTAL
Intervention: Mandibular single-implant overdentures
Number of subjects: 22

Group type: COMPARATOR
Intervention: Complete dentures
Number of subjects: 22
Study: 27634790

Group type: EXPERIMENTAL
Intervention: Combination therapy (3 mg eszopiclone and 40% oxygen)
Number of subjects: 20
Study: 24603733

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) applied by the therapist
Number of subjects: 14

Group type: COMPARATOR
Intervention: Proprioceptive neuromuscular facilitation (PNF) self-administered using an elastic tube
Number of subjects: 14
Study: 23217162

Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 70
Study: 20214069

Group type: EXPERIMENTAL
Intervention: Warming needle at spinal nerves in front of transverse posterior tubercle of cervical vertebra
Number of subjects: 180

Group type: COMPARATOR
Intervention: Acupuncture at acupoints of cervical Jiaji (EX‐B 2)
Number of subjects: 180
Study: 17411463

Group type: EXPERIMENTAL
Intervention: Intervention group with parental support
Number of subjects: 2991

Group type: EXPERIMENTAL
Intervention: Intervention group without parental support
Number of subjects: 2991

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2991
Study: 15772683

Group type: EXPERIMENTAL
Intervention: Trimix (Tx) with varying doses of phentolamine (1 mg) and papaverine (5, 10, or 20 mg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Prostaglandin E1 (PgE1) at doses of 2.5, 5, or 10 microg
Number of subjects: 180
Study: 12033713

Group type: EXPERIMENTAL
Intervention: Gyrification patterns in individuals with WS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Typically developing control participants
Number of subjects: 17